This was the stock's fourth consecutive day of gains.

In a regulatory filing, Vertex Pharmaceuticals (VRTX) chief scientific officer David Altshuler disclosed the sale of 3,231 common shares of the ...

Those who already own VRTX stock may retain it for some time to see if its CF sales continue to rise and how the Journavx and ...

Are you reluctant to invest in stocks right now? That's understandable. Fear, uncertainty, and doubt have become the norm in ...

Latigo Biotherapeutics raises $150M Series B to advance Nav1.8 inhibitors for pain, competing with Vertex's Journavx.